171 related articles for article (PubMed ID: 15564141)
1. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
4. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells.
Kobari L; Pflumio F; Giarratana M; Li X; Titeux M; Izac B; Leteurtre F; Coulombel L; Douay L
Exp Hematol; 2000 Dec; 28(12):1470-80. PubMed ID: 11146169
[TBL] [Abstract][Full Text] [Related]
6. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
7. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors.
Guenechea G; Gan OI; Inamitsu T; Dorrell C; Pereira DS; Kelly M; Naldini L; Dick JE
Mol Ther; 2000 Jun; 1(6):566-73. PubMed ID: 10933981
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expansion of cord blood-CD34(+) cells using IGFBP2 and Angptl-5 impairs short-term lymphoid repopulation in vivo.
Ventura Ferreira MS; Labude N; Walenda G; Adamzyk C; Wagner W; Piroth D; Müller AM; Knüchel R; Hieronymus T; Zenke M; Jahnen-Dechent W; Neuss S
J Tissue Eng Regen Med; 2013 Dec; 7(12):944-54. PubMed ID: 22653714
[TBL] [Abstract][Full Text] [Related]
9. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.
Carbonaro DA; Jin X; Cotoi D; Mi T; Yu XJ; Skelton DC; Dorey F; Kellems RE; Blackburn MR; Kohn DB
Blood; 2008 Jun; 111(12):5745-54. PubMed ID: 18356486
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
11. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells.
Cavazzana-Calvo M; Hacein-Bey S; de Saint Basile G; De Coene C; Selz F; Le Deist F; Fischer A
Blood; 1996 Nov; 88(10):3901-9. PubMed ID: 8916956
[TBL] [Abstract][Full Text] [Related]
12. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
13. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
[No Abstract] [Full Text] [Related]
14. gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures.
Hacein-Bey S; Basile GD; Lemerle J; Fischer A; Cavazzana-Calvo M
Blood; 1998 Dec; 92(11):4090-7. PubMed ID: 9834214
[TBL] [Abstract][Full Text] [Related]
15. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
16. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells.
Hacein-Bey S; Gross F; Nusbaum P; Hue C; Hamel Y; Fischer A; Cavazzana-Calvo M
Hum Gene Ther; 2001 Feb; 12(3):291-301. PubMed ID: 11177565
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells.
Rossmanith T; Schröder B; Bug G; Müller P; Klenner T; Knaus R; Hoelzer D; Ottmann OG
Stem Cells; 2001; 19(4):313-20. PubMed ID: 11463951
[TBL] [Abstract][Full Text] [Related]
19. CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo.
Young JC; Lin K; Hansteen G; Travis M; Murray LJ; Jaing L; Scollay R; Hill BL
Exp Hematol; 1999 Jun; 27(6):994-1003. PubMed ID: 10378888
[TBL] [Abstract][Full Text] [Related]
20. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
